MMP + fluorouracil

MMP + fluorouracil is a combination therapy consisting of an agent targeting matrix metalloproteinases (MMPs) and the antimetabolite chemotherapeutic drug 5-fluorouracil. While 5-fluorouracil (5-FU) is a well-established small molecule that inhibits thymidylate synthase, thereby disrupting DNA synthesis and inducing cell cycle arrest and apoptosis in rapidly dividing cells, "MMP" refers to matrix metalloproteinases—a family of enzymes involved in the degradation of extracellular matrix components. In cancer therapy, MMP inhibitors have been explored for their potential to reduce tumor invasion and metastasis by blocking these enzymes' activity. The combination aims to leverage the cytotoxic effects of 5-fluorouracil with the anti-invasive properties of MMP inhibition for synergistic antitumor efficacy. However, there is no evidence from current literature or clinical trials that a specific marketed product or widely recognized investigational drug exists under the name "MMP + fluorouracil." Most studies involving 5-fluorouracil combinations reference other agents such as steroids (e.g., triamcinolone), parecoxib, or other chemotherapeutics[1][2][3]. Therefore, this appears to be either an experimental concept or a non-standardized combination.